1. Home
  2. LEDS vs AKTX Comparison

LEDS vs AKTX Comparison

Compare LEDS & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SemiLEDS Corporation

LEDS

SemiLEDS Corporation

HOLD

Current Price

$1.23

Market Cap

12.2M

Sector

Technology

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.15

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEDS
AKTX
Founded
2005
N/A
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.2M
11.5M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
LEDS
AKTX
Price
$1.23
$0.15
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.53
AVG Volume (30 Days)
10.5K
341.3K
Earning Date
04-09-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
53.12
N/A
EPS
N/A
N/A
Revenue
$43,009,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
729.81
N/A
52 Week Low
$1.11
$0.13
52 Week High
$3.37
$1.58

Technical Indicators

Market Signals
Indicator
LEDS
AKTX
Relative Strength Index (RSI) 34.53 24.57
Support Level N/A N/A
Resistance Level $2.02 $0.27
Average True Range (ATR) 0.07 0.03
MACD -0.02 -0.01
Stochastic Oscillator 26.67 3.44

Price Performance

Historical Comparison
LEDS
AKTX

About LEDS SemiLEDS Corporation

SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: